References
- Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175–1186. doi:10.2147/OPTH.S33372
- Finger RP, Guymer RH, Gillies MC, Keeffe JE. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1246–1251. doi:10.1016/j.ophtha.2013.12.032
- Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug Type for 1 Year in the IRIS registry. Ophthalmology. 2018;125(4):522–528. doi:10.1016/j.ophtha.2017.10.010
- Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5(5):CD012208. doi:10.1002/14651858.CD012208
- Campa C, Alivernini G, Bolletta E, Parodi MB, Perri P. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets. 2016;17(3):328–336. doi:10.2174/1573399811666150615151324
- Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. The evolving treatment of diabetic retinopathy. Clin Ophthalmol. 2020;14:653–678. doi:10.2147/OPTH.S236637
- Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the Phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99. doi:10.1016/j.ophtha.2020.06.028
- Chakraborty D, Stewart MW, Sheth JU, et al. Real-world safety outcomes of intravitreal ranibizumab biosimilar (razumab) therapy for chorioretinal diseases. Ophthalmol Ther. 2021;10(2):337–348. doi:10.1007/s40123-021-00345-2
- European Medicines Agency. ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting; 1995. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf. Accessed July 9, 2021.
- Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259(8):2181–2192. doi:10.1007/s00417-020-05048-1
- Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–1304. doi:10.1016/j.ophtha.2017.03.057
- Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
- Bulirsch LM, Saßmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021;bjophthalmol-2020-318672. doi:10.1136/bjophthalmol-2020-318672
- Sharma A, Kumar N, Parachuri N, et al. Brolucizumab-early real-world experience: BREW study. Eye (Lond). 2021;35(4):1045–1047. doi:10.1038/s41433-020-1111-x
- Enríquez AB, Baumal CR, Crane AM, et al. Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(4):441–448. doi:10.1001/jamaophthalmol.2020.7085
- Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med. 2021;10(13):2758. doi:10.3390/jcm10132758
- Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092–1101. doi:10.1016/j.ophtha.2013.11.031
- Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013;2013:943409. doi:10.1155/2013/943409
- Johnson D, Sharma S. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2013;24(3):205–212. doi:10.1097/ICU.0b013e32835f8ec0
- Daien V, Nguyen V, Essex RW, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018;125(1):66–74. doi:10.1016/j.ophtha.2017.07.005
- Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–1359. doi:10.1016/j.ophtha.2020.04.017
- Beovu®. Post-marketing data in patients with wet AMD; 2021. Available from: https://www.brolucizumab.info/post-marketing-data. Accessed July 9, 2021.
- Sharma A, Kumar N, Parachuri N, et al. Brolucizumab and immunogenicity. Eye (Lond). 2020;34(10):1726–1728. doi:10.1038/s41433-020-0853-9
- Paalani M, Lee JW, Haddad E, Tonstad S. Determinants of inflammatory markers in a bi-ethnic population. Ethn Dis. 2011;21(2):142–149.
- Angeles-Han ST, McCracken C, Yeh S, et al. The association of race with childhood uveitis. Am J Ophthalmol. 2015;160(5):919–928.e1. doi:10.1016/j.ajo.2015.08.002
- Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the pacific ocular inflammation study. JAMA Ophthalmol. 2013;131(11):1405–1412. doi:10.1001/jamaophthalmol.2013.4237
- Chauhan K, Rosenbaum J. Effect of age, race, sex and state of residence on ocular inflammatory and infectious diseases in the United States. Invest Ophthalmol Vis Sci. 2020;61(7):2056.
- Yao S, Hong CC, Ruiz-Narváez EA, et al. Genetic ancestry and population differences in levels of inflammatory cytokines in women: role for evolutionary selection and environmental factors. PLoS Genet. 2018;14(6):e1007368. doi:10.1371/journal.pgen.1007368
- Wen X, Hu X, Miao L, et al. Epigenetics, microbiota, and intraocular inflammation: new paradigms of immune regulation in the eye. Prog Retin Eye Res. 2018;64:84–95. doi:10.1016/j.preteyeres.2018.01.001
- Esen F, Alhan O, Kuru P, Sahin O. Safety assessment and power analyses in published anti-vascular endothelial growth factor randomized controlled trials. Am J Ophthalmol. 2016;169:68–72. doi:10.1016/j.ajo.2016.06.019